Search

Sabah Oney

from Palo Alto, CA
Age ~42
Get Report
Connected to:
Andrea M Oney, 58Christina Oney, 54Jamal L Oney, 31Johnny W Oney, 67Kaitlin Oney, 30Kevin G Oney, 40Kirk R Oney, 60Mary K Oney, 73Patricia A Oney, 57Shannon E Oney, 45

Sabah Oney Phones & Addresses

  • Palo Alto, CA
  • San Francisco, CA
  • 23 Forest Green Dr, Durham, NC 27705

Work

Company: Ariosa diagnostics Sep 2012 Address: San Jose, CA Position: Director of business development

Education

School / High School: Stanford University Graduate School of Business 2010 to 2012

Skills

Biotechnology • Strategy • Business Strategy • Oncology • Entrepreneurship • Lifesciences • Start Ups • Business Development • Healthcare • Life Sciences • Clinical Development • Molecular Biology • R&D • Pharmaceutical Industry • Cross Functional Team Leadership • Genomics • Medical Devices • Data Analysis • Research and Development • Cell Culture • Commercialization • Assay Development • Biochemistry • Clinical Trials • Immunology • Genetics • Cell • Pcr • Cancer • Protein Chemistry • Microbiology • Fda • Patents • U.s. Food and Drug Administration

Languages

English • Turkish

Industries

Biotechnology

Resumes

Resumes

Sabah Oney Photo 1

Chief Business Officer

View page
Location:
South San Francisco, CA
Industry:
Biotechnology
Work:
Ariosa Diagnostics - San Jose, CA since Sep 2012
Director of Business Development
Genentech, Inc Jun 2011 - Sep 2011
MBA Intern
b3 bio, Inc Jul 2008 - Jul 2010
Senior Scientist
Duke University Medical Center Aug 2003 - May 2008
Ph.D. Candidate
Education:
Stanford University Graduate School of Business 2010 - 2012
Duke University 2003 - 2008
University of Kansas 1999 - 2003
Turk Maarif Koleji 1993 - 1999
Skills:
Biotechnology
Strategy
Business Strategy
Oncology
Entrepreneurship
Lifesciences
Start Ups
Business Development
Healthcare
Life Sciences
Clinical Development
Molecular Biology
R&D
Pharmaceutical Industry
Cross Functional Team Leadership
Genomics
Medical Devices
Data Analysis
Research and Development
Cell Culture
Commercialization
Assay Development
Biochemistry
Clinical Trials
Immunology
Genetics
Cell
Pcr
Cancer
Protein Chemistry
Microbiology
Fda
Patents
U.s. Food and Drug Administration
Languages:
English
Turkish

Publications

Us Patents

Focused Libraries, Functional Profiling, Laser Selex, And Deselex

View page
US Patent:
20090264508, Oct 22, 2009
Filed:
Sep 15, 2006
Appl. No.:
11/992125
Inventors:
Bruce A. Sullenger - Chapel Hill NC, US
Juliana M. Layzer - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Sabah Oney - Durham NC, US
International Classification:
A61K 31/7088
C40B 50/06
C07H 21/02
A61P 35/00
US Classification:
514 44 R, 506 26, 536 231
Abstract:
Focused aptamer libraries are constructed in accordance with a proteome (i.e., complex mixture of native biomolecules). The libraries may be screened to identify one or more candidate aptamers with desired biological activities other than specific binding to a target. Aptamers which are selected or derivatives thereof may be used for those specific activities in biological systems. Any combination of deconvoluting a focused library (functional profiling), increasing frequencies of particular aptamers in a focused library (Laser SELEX), and decreasing frequencies of particular aptamers in a focused library (DeSELEX) may be performed prior to assaying biological activity.

Method Of Modulating The Activity Of A Nucleic Acid Molecule

View page
US Patent:
20100184822, Jul 22, 2010
Filed:
Sep 30, 2009
Appl. No.:
12/588016
Inventors:
Bruce A. Sullenger - Durham NC, US
Sabah Oney - Durham NC, US
Tung Suet Ruby Lam - Durham NC, US
Kam Leong - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 31/7088
C12Q 1/68
US Classification:
514 44 A, 514 44 R, 435 6
Abstract:
The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.

Reversible Platelet Inhibition

View page
US Patent:
20120264815, Oct 18, 2012
Filed:
Nov 14, 2011
Appl. No.:
13/296045
Inventors:
Bruce A. SULLENGER - Durham NC, US
Shahid Nimjee - Durham NC, US
Sabah Oney - Palo Alto CA, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 31/7088
A61P 7/04
A61K 31/711
A61P 7/02
C07H 21/00
C07H 21/04
US Classification:
514 44 R, 536 231
Abstract:
The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Reversible Platelet Inhibition

View page
US Patent:
20160289297, Oct 6, 2016
Filed:
Jul 28, 2014
Appl. No.:
14/444431
Inventors:
- Durham NC, US
Shahid Nimjee - Durham NC, US
Sabah Oney - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
C07K 14/705
Abstract:
The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Method Of Modulating The Activity Of A Nucleic Acid Molecule

View page
US Patent:
20160250165, Sep 1, 2016
Filed:
May 13, 2016
Appl. No.:
15/154539
Inventors:
- Durham NC, US
Sabah Oney - Durham NC, US
Tung Suet Ruby Lam - Durham NC, US
Kam Leong - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 31/164
C12N 15/115
G01N 33/53
A61K 31/14
A61K 31/132
Abstract:
The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.
Control profile
Sabah Oney from Palo Alto, CA, age ~42 Get Report